Cargando…

Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis

IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti–vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tong, Sun, Junran, Min, Jingyu, Zhou, Shuangwen, Zhu, Xiaolin, Jia, Huixun, Sun, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377608/
https://www.ncbi.nlm.nih.gov/pubmed/34410325
http://dx.doi.org/10.1001/jamaophthalmol.2021.3096
_version_ 1783740690716426240
author Li, Tong
Sun, Junran
Min, Jingyu
Zhou, Shuangwen
Zhu, Xiaolin
Jia, Huixun
Sun, Xiaodong
author_facet Li, Tong
Sun, Junran
Min, Jingyu
Zhou, Shuangwen
Zhu, Xiaolin
Jia, Huixun
Sun, Xiaodong
author_sort Li, Tong
collection PubMed
description IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti–vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been systematically evaluated. OBJECTIVE: To evaluate the safety outcomes of IVI with anti-VEGF agents in the OR vs office-based setting. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched from inception to July 2020. STUDY SELECTION: Eligible studies reporting on patients who received IVIs with anti-VEGF drugs with a clearly stated injection setting of the office or OR. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened studies, extracted data, and assessed risk of bias. A meta-analysis was conducted to determine the rates of endophthalmitis (EO) and culture-positive EO. MAIN OUTCOMES AND MEASURES: Rates of EO and culture-positive EO following anti-VEGF IVIs in the OR and office-based setting. RESULTS: Thirty-one studies with a total of 1 275 815 injections were included. Comparative analysis suggested no difference between rates of EO after IVIs performed in the office and OR settings (odds ratio, 3.06; 95% CI, 0.07-139.75; P = .57; I(2) = 80%) were identified, yet a higher rate of culture-positive EO was found in the office setting (odds ratio, 21.52; 95% CI, 2.39-193.55; P = .006; I(2) = 0%). The pooled rates of EO following anti-VEGF IVIs were 0.03% (95% CI, 0.03-0.04) and 0.02% (95% CI, 0.01-0.04) in office and OR settings, respectively, and the pooled rates of culture-positive EO were 0.01% (95% CI, 0.01-0.02) and 0.01% (95% CI, 0-0.02). The pooled rates of other ocular and systemic adverse events were low. CONCLUSIONS AND RELEVANCE: The rate of clinically suspected or culture-positive EO following anti-VEGF IVIs was low whether the procedure was performed in the office or OR setting. Bacterial spectrum could differ between the 2 settings. This meta-analysis could not determine if it is more appropriate to give treatment in the OR for safety reasons in low-income compared with higher-income regions in the world.
format Online
Article
Text
id pubmed-8377608
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-83776082021-09-02 Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis Li, Tong Sun, Junran Min, Jingyu Zhou, Shuangwen Zhu, Xiaolin Jia, Huixun Sun, Xiaodong JAMA Ophthalmol Original Investigation IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti–vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been systematically evaluated. OBJECTIVE: To evaluate the safety outcomes of IVI with anti-VEGF agents in the OR vs office-based setting. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched from inception to July 2020. STUDY SELECTION: Eligible studies reporting on patients who received IVIs with anti-VEGF drugs with a clearly stated injection setting of the office or OR. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened studies, extracted data, and assessed risk of bias. A meta-analysis was conducted to determine the rates of endophthalmitis (EO) and culture-positive EO. MAIN OUTCOMES AND MEASURES: Rates of EO and culture-positive EO following anti-VEGF IVIs in the OR and office-based setting. RESULTS: Thirty-one studies with a total of 1 275 815 injections were included. Comparative analysis suggested no difference between rates of EO after IVIs performed in the office and OR settings (odds ratio, 3.06; 95% CI, 0.07-139.75; P = .57; I(2) = 80%) were identified, yet a higher rate of culture-positive EO was found in the office setting (odds ratio, 21.52; 95% CI, 2.39-193.55; P = .006; I(2) = 0%). The pooled rates of EO following anti-VEGF IVIs were 0.03% (95% CI, 0.03-0.04) and 0.02% (95% CI, 0.01-0.04) in office and OR settings, respectively, and the pooled rates of culture-positive EO were 0.01% (95% CI, 0.01-0.02) and 0.01% (95% CI, 0-0.02). The pooled rates of other ocular and systemic adverse events were low. CONCLUSIONS AND RELEVANCE: The rate of clinically suspected or culture-positive EO following anti-VEGF IVIs was low whether the procedure was performed in the office or OR setting. Bacterial spectrum could differ between the 2 settings. This meta-analysis could not determine if it is more appropriate to give treatment in the OR for safety reasons in low-income compared with higher-income regions in the world. American Medical Association 2021-08-19 2021-10 /pmc/articles/PMC8377608/ /pubmed/34410325 http://dx.doi.org/10.1001/jamaophthalmol.2021.3096 Text en Copyright 2021 Li T et al. JAMA Ophthalmology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Li, Tong
Sun, Junran
Min, Jingyu
Zhou, Shuangwen
Zhu, Xiaolin
Jia, Huixun
Sun, Xiaodong
Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
title Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
title_full Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
title_fullStr Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
title_full_unstemmed Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
title_short Safety of Receiving Anti–Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis
title_sort safety of receiving anti–vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377608/
https://www.ncbi.nlm.nih.gov/pubmed/34410325
http://dx.doi.org/10.1001/jamaophthalmol.2021.3096
work_keys_str_mv AT litong safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis
AT sunjunran safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis
AT minjingyu safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis
AT zhoushuangwen safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis
AT zhuxiaolin safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis
AT jiahuixun safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis
AT sunxiaodong safetyofreceivingantivascularendothelialgrowthfactorintravitrealinjectioninofficebasedvsoperatingroomsettingsametaanalysis